About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
R
The TAPUR Study: Evaluating Targeted Therapies Based on Genetic Alterations in Diverse Cancer Types
By
University of Miami Sylvester Comprehensive Cancer Center
FEATURING
Richard Schilsky
By
University of Miami Sylvester Comprehensive Cancer Center
FEATURING
Richard Schilsky
98 views
August 21, 2024
1 Comment
Login to view comments.
Click here to Login
Featured Video
17:33
AstraZeneca Oncology
First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…
Feat.
S. Lewin
Featured Video
06:14
Lilly Medical Affairs
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
Feat.
J. O’Shaughnessy
Related Content
AUTOPLAY
ON
25:08
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice
Feat.
S. Tolaney,
H. Rugo
12:14
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…
Feat.
P. Tarantino
07:23
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…
Feat.
R. O'Regan
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
09:55
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…
Feat.
E. Hamilton
09:19
Insights from 2023 SABCS
SABCS 2023 Insights: "Biology or Stage? Tailoring Treatment for…
Feat.
K. Kalinsky
27:01
Scripps Health
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
Feat.
S. Sammons
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
10:34
Sara Tolaney
ASCO® 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
17:19
Moffitt Cancer Center
Year in Review: Colorectal Cancer
Feat.
R. Kim,
T. Biachi
16:19
Wassim Mchayleh
Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…
21:01
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Panel Discussion: "Key Updates in Breast Cance…
Feat.
S. Tolaney,
H. Rugo
13:49
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "NATALEE Trial - Baseline Characteristics …
Feat.
D. Yardley
24:14
Masterclasses in Dermatology
Advances in the Treatment of Melanoma
Feat.
D. Fisher
12:07
Sara Tolaney
ESMO 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
21:31
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…
Feat.
S. Tolaney,
H. Rugo
11:13
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Development and Validation of RSClinN+ To…
Feat.
L. Pusztai
35:23
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "My Personal Highlights in Melanoma"
Feat.
S. Patel
17:12
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…
Feat.
A. Faso,
B. Patel,
K. Chen
13:47
Stanford Medicine
HR+ Advanced/Metastatic BC Treatment Options: Refining Endocrine Sen…
Feat.
M. Dolezal
